Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 1 (3), 129-134

Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure

Affiliations

Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure

Brian Bressler et al. J Can Assoc Gastroenterol.

Abstract

Background: The efficacy of golimumab to induce and maintain remission in biologic-naïve patients with ulcerative colitis (UC) is established from placebo-controlled trials. However, golimumab's real-world effectiveness, important to physicians and payers, remains unexplored.

Aim: The goal of this study was to describe real-world use and rate of persistence among UC patients with golimumab therapy and to assess factors that predict discontinuation during golimumab maintenance treatment.

Methods: A retrospective study of UC patients receiving golimumab maintenance therapy (August 2012-August 2015) was conducted on dosing data from a national case management program. Treatment persistence, defined as time from index prescription to the last dose (gap in dose >60 days), was assessed using Kaplan-Meier survival analysis. Predictors of treatment persistence were explored with Cox proportional hazards regression.

Results: One hundred thirty-six patients (50.7% male) with a mean (SD) age of 44.4 (15.6) years were included. At golimumab initiation, 72.1% were naïve to anti-TNFs; 77.2% received 200 mg, while 4.4% and 18.4% received 50 mg and 100 mg, respectively, every 4 weeks (induction therapy). The median time to discontinuation was 530 days, with a cumulative probability of 63% to remain on therapy at one year. Age, gender, golimumab induction, golimumab maintenance dose and prior anti-TNF exposure were not significantly associated with treatment persistence. Dose adjustment occurred in 7.4% of patients during maintenance treatment.

Conclusions: Overall, the persistence rate of golimumab observed in the current real-world study is similar to that described in previous single-centre UC cohorts and consistent with that seen in controlled clinical trials.

Keywords: Biologics; Compliance/adherence; Inflammatory bowel disease; Ulcerative colitis.

Figures

Figure 1.
Figure 1.
Persistence on golimumab therapy (nonpersistence >60 days gap)—overall. median persistence was 530 days.
Figure 2.
Figure 2.
Persistence on golimumab therapy (nonpersistence >60 days gap) by prior anti-TNF experience.
Figure 3.
Figure 3.
Persistence on golimumab therapy (nonpersistence >60 days gap) by gender.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

References

    1. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management. J Crohns Colitis 2012;6(10):991–1030. - PubMed
    1. Kornbluth A, Sachar DB.; Practice Parameters Committee of the American College of Gastroenterology Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105(3):501–23; quiz 524. - PubMed
    1. Bressler B, Marshall JK, Bernstein CN, et al. ; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto consensus. Gastroenterology 2015;148(5):1035–58.e1033. - PubMed
    1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76. - PubMed
    1. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142(2):257–65. e251–3. - PubMed

LinkOut - more resources

Feedback